MARKET

PEPG

PEPG

PepGen Inc
NASDAQ
2.375
-0.020
-0.84%
Opening 11:22 03/17 EDT
OPEN
2.390
PREV CLOSE
2.395
HIGH
2.390
LOW
2.290
VOLUME
49.32K
TURNOVER
--
52 WEEK HIGH
19.30
52 WEEK LOW
1.160
MARKET CAP
77.64M
P/E (TTM)
-0.8336
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PEPG last week (0310-0314)?
Weekly Report · 11h ago
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Barchart · 03/10 15:05
Weekly Report: what happened at PEPG last week (0303-0307)?
Weekly Report · 03/10 09:03
PepGen Inc. Faces Clinical Trial Challenges and Competitive Pressures Leading to Sell Rating
TipRanks · 03/05 11:37
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls
Benzinga · 03/04 18:41
Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation
Simply Wall St · 03/04 17:27
BUZZ-PepGen slumps after pausing mid-stage study of Duchenne drug
Reuters · 03/04 14:04
PepGen slides after pause on mid-stage Duchenne trial
Seeking Alpha · 03/04 13:21
More
About PEPG
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Webull offers PepGen Inc stock information, including NASDAQ: PEPG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEPG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PEPG stock methods without spending real money on the virtual paper trading platform.